Generic Drug Super Office Takes Shape
Generic Drug Super Office Takes Shape
The Office of Generic Drugs (OGD) is readying for its shift to a larger and more complex organization on par with offices for new drugs, drug safety, and compliance in FDA’s Center for Drug Evaluation and Research (CDER). Under the new generic drug user fee program (GDUFA), OGD is expanding its staff, working through a massive backlog of abbreviated new drug applications (ANDAs) and prior approval supplements, and assessing the completeness of drug master files in addition to evaluating more ANDAs and supplements.
The expanded OGD will have a strong clinical presence to assess bioequivalence and other tests, explained OGD acting director Kathleen Uhl at the Generic Pharmaceutical Association’s technical conference in October. An office of research will carry out studies to support development of more complex generic dosage forms, while an office of generic drug policy will develop guidance and internal procedures, Uhl noted. Chemists and microbiologists will join the new Office of Pharmaceutical Quality (OPQ), when it is established next year to unify the oversight of manufacturing and quality performance for all drugs, including biotech therapies.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
